Last updated: February 21, 2026
What is NDC 00121-0770?
NDC 00121-0770 identifies a specific pharmaceutical product within the FDA's National Drug Code system. According to the FDA records, this NDC refers to Rituximab (brand name: Rituxan), produced by Genentech, a Roche company. It is used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions.
Market Landscape
Current Market Size
The global rituximab market was valued at approximately USD 4.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7% from 2023 to 2030, reaching around USD 8 billion by 2030.
Key Market Drivers
- Increasing prevalence of B-cell non-Hodgkin lymphomas and autoimmune diseases.
- Expanding indications for rituximab, including new autoimmune and oncologic therapies.
- Growth in biosimilars, increasing access and reducing costs.
Competitive Environment
The product faces competition primarily from biosimilars approved since 2017, including:
- Celltrion's Truxima
- Sandoz's Ruxience
- Adalimumab biosimilars that target autoimmune conditions.
Major branded competitors include Merck's Lemtrada and newer biologics like Ofatumumab.
Distribution Channels
Hospital pharmacies hold approximately 60% of rituximab sales, while outpatient clinics and specialty pharmacies account for the remainder. The shift toward biosimilars has increased market penetration in outpatient settings.
Price Analysis
Historical Pricing
- Brand-name Rituxan (2017-2022): Wholesale acquisition cost (WAC) ranged from USD 4,300 to USD 4,550 per 500 mg vial.
- Biosimilars: Priced approximately 15-20% lower than brand-name, with WACs around USD 3,300 to USD 3,700 per 500 mg vial.
Price Trends
Since biosimilars entered the market, the average price per course of therapy decreased by roughly 25%. The per-vial price has stabilized but is expected to decline further with increased biosimilar competition.
Projected Pricing (2023-2030)
| Year |
Estimated WAC per 500 mg vial |
Remarks |
| 2023 |
USD 3,600 |
Biosimilar competition stabilizes prices |
| 2025 |
USD 3,200 |
Increased biosimilar adoption |
| 2030 |
USD 2,800 |
Further biosimilar entry and market penetration |
Pricing assumptions
- Biosimilar proliferation will continue, with genericization savings further lowering costs.
- Market shifts toward outpatient infusion settings favor lower-cost formulations.
- Price reductions may accelerate if patent challenges or new approved biosimilars enter the market early.
Regulatory and Policy Factors
- Patent expirations: The original patent for Rituximab expired in 2018, enabling biosimilar development.
- Biosimilar approvals: The FDA has approved multiple biosimilars since 2017, influencing pricing and market dynamics.
- Reimbursement policies: CMS and private insurers increasingly favor biosimilars, incentivizing providers to switch.
Market Risks and Opportunities
Risks
- Rapid biosimilar uptake: Could erode margins further.
- Regulatory hurdles: Delays in biosimilar approvals or patent litigations.
- Supply chain issues: Affecting availability and pricing.
Opportunities
- Extended indications: Additional FDA approvals could expand the market.
- Pricing strategies: Innovator companies can retain market share through value-added services.
- Emerging markets: Increased adoption in developing countries offers growth potential.
Key Takeaways
- NDC 00121-0770 refers to rituximab, a leading biologic with a significant market presence.
- The global rituximab market is growing at a CAGR of approximately 7% through 2030.
- Biosimilars are pushing prices downward, with expected per-vial prices dropping to USD 2,800 by 2030.
- Price reductions are driven by increased biosimilar competition, patent expirations, and policy shifts favoring biosimilars.
- Market entry barriers and patent litigations remain risks, but innovations and emerging markets create opportunities.
FAQs
1. How does biosimilar competition impact the price of rituximab?
Biosimilars typically sell at 15-20% lower prices than the reference product, leading to significant reductions in market prices as their adoption increases.
2. What is the main driver for rituximab's market growth?
The increase in indications and prevalence of target diseases, combined with expanded biosimilar options, fuel market growth.
3. When did patent expiration open the market for biosimilars?
The original patent for rituximab expired in 2018, allowing biosimilar manufacturers to enter soon after.
4. Are there upcoming regulatory changes that could affect rituximab pricing?
Potential biosimilar approvals and policy shifts favoring biosimilars could accelerate price reductions.
5. What markets outside the U.S. are significant for rituximab?
Europe, Japan, and emerging economies account for substantial shares, with growing adoption due to expanding healthcare infrastructure.
References
[1] Grand View Research. (2022). Rituximab market size, share & trends analysis report.
[2] U.S. Food and Drug Administration. (2022). Biosimilar and interchangeable products.
[3] IQVIA. (2023). US pharmaceutical market analysis report.
[4] MarketWatch. (2023). Global rituximab market forecast.
[5] Food and Drug Administration. (2018). FDA approves first biosimilar for cancer treatment.
Note: The data presented incorporates aggregate industry insights and publicly available market reports.
